Skip to content

WHWK WHWK Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Pfizer logo
PfizerPFE
$1.76B+18.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.97B-4.0%
Gilead Sciences logo
Gilead SciencesGILD
$7.63B-3.8%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$157.52M+21.2%

Other financials

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$23.5M-54.6%
Net income-$22.2M-130%
EPS (diluted)-$0.32-117%

Balance sheet

See full
Total debt$833.0K-34.3%
Total equity$116.2M-47.6%
Total assets$127.2M-45.6%

Cash flow

See full
Operating cash flow-$22.2M-87.2%
CapEx--100%
Free cash flow-$22.2M-78.9%

Valuation

See full
Market cap$226.49M+131%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-1,601.1%-1,985pp
Net margin-288.3%+61.6pp
FCF margin-1,371.4%-1,730pp

Returns & leverage

See full
Return on equity-68.5%-86.2pp
Debt / equity0.0×
Current ratio11.4×-7.6×

Where this comes from

Reported directly by WHWK in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: WHWK’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about WHWK's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is WHWK's cash & equivalents?
WHWK (WHWK) reported cash & equivalents of $34.79M in Q1 2026.
How has WHWK's cash & equivalents changed year-over-year?
WHWK's cash & equivalents decreased by 84.7% year-over-year, from $227.57M to $34.79M.
What is the long-term trend for WHWK's cash & equivalents?
Over 4 years (2021 to 2025), WHWK's cash & equivalents has grown at a -29.1% compound annual growth rate (CAGR), from $148.99M to $37.57M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.